Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
OCRX's Cash to Debt is ranked higher than
88% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. OCRX: No Debt )
OCRX' s 10-Year Cash to Debt Range
Min: 0.68   Max: No Debt
Current: No Debt

Equity to Asset 0.92
OCRX's Equity to Asset is ranked higher than
97% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. OCRX: 0.92 )
OCRX' s 10-Year Equity to Asset Range
Min: -1.09   Max: 0.96
Current: 0.92

-1.09
0.96
F-Score: 3
Z-Score: 17.19
M-Score: -11.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -18034.12
OCRX's Operating margin (%) is ranked lower than
58% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. OCRX: -18034.12 )
OCRX' s 10-Year Operating margin (%) Range
Min: -18034.12   Max: -63.42
Current: -18034.12

-18034.12
-63.42
Net-margin (%) -20604.71
OCRX's Net-margin (%) is ranked lower than
58% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. OCRX: -20604.71 )
OCRX' s 10-Year Net-margin (%) Range
Min: -20604.71   Max: -77.84
Current: -20604.71

-20604.71
-77.84
ROE (%) -38.81
OCRX's ROE (%) is ranked lower than
52% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. OCRX: -38.81 )
OCRX' s 10-Year ROE (%) Range
Min: -160.04   Max: -38.81
Current: -38.81

-160.04
-38.81
ROA (%) -33.80
OCRX's ROA (%) is ranked lower than
52% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. OCRX: -33.80 )
OCRX' s 10-Year ROA (%) Range
Min: -230.64   Max: -30.78
Current: -33.8

-230.64
-30.78
ROC (Joel Greenblatt) (%) -25981.36
OCRX's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. OCRX: -25981.36 )
OCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25981.36   Max: -415.9
Current: -25981.36

-25981.36
-415.9
Revenue Growth (%) -97.60
OCRX's Revenue Growth (%) is ranked lower than
56% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. OCRX: -97.60 )
OCRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -97.6
Current: -97.6

EBITDA Growth (%) -82.20
OCRX's EBITDA Growth (%) is ranked lower than
55% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. OCRX: -82.20 )
OCRX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -82.2
Current: -82.2

EPS Growth (%) -84.10
OCRX's EPS Growth (%) is ranked lower than
54% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. OCRX: -84.10 )
OCRX' s 10-Year EPS Growth (%) Range
Min: 0   Max: -84.1
Current: -84.1

» OCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

OCRX Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

OCRX Guru Trades in Q4 2013

Jim Simons 13,949 sh (New)
» More
Q1 2014

OCRX Guru Trades in Q1 2014

Jim Simons 37,049 sh (+165.6%)
» More
Q2 2014

OCRX Guru Trades in Q2 2014

Jim Simons 63,749 sh (+72.07%)
» More
» Details

Insider Trades

Latest Guru Trades with OCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Ocera Therapeutics Inc

Three Insider Buys at 52-Week Lows
Over the past month three companies have reported insider buys as their price hits or nears 52-week lows. Looking at insider buys while they’re trading at low prices can offer an excellent time to buy into a company or further your research on the company. Peter Lynch once offered that insiders will sell their shares in a company for many reasons, but they will only invest it if they think that the share price will rise.

Read more...

Ratios

vs
industry
vs
history
P/B 2.49
OCRX's P/B is ranked higher than
71% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. OCRX: 2.49 )
OCRX' s 10-Year P/B Range
Min: 0.85   Max: 10.49
Current: 2.49

0.85
10.49
EV-to-EBIT -2.01
OCRX's EV-to-EBIT is ranked lower than
51% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. OCRX: -2.01 )
OCRX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.01

Current Ratio 11.75
OCRX's Current Ratio is ranked higher than
96% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. OCRX: 11.75 )
OCRX' s 10-Year Current Ratio Range
Min: 0.62   Max: 21.99
Current: 11.75

0.62
21.99
Quick Ratio 11.75
OCRX's Quick Ratio is ranked higher than
96% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. OCRX: 11.75 )
OCRX' s 10-Year Quick Ratio Range
Min: 0.62   Max: 21.99
Current: 11.75

0.62
21.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.61
OCRX's Price/Net Cash is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. OCRX: 2.61 )
OCRX' s 10-Year Price/Net Cash Range
Min: 1.23   Max: 10.42
Current: 2.61

1.23
10.42
Price/Net Current Asset Value 2.61
OCRX's Price/Net Current Asset Value is ranked higher than
98% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. OCRX: 2.61 )
OCRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.17   Max: 9.89
Current: 2.61

1.17
9.89
Price/Tangible Book 2.55
OCRX's Price/Tangible Book is ranked higher than
81% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. OCRX: 2.55 )
OCRX' s 10-Year Price/Tangible Book Range
Min: 1.04   Max: 7.99
Current: 2.55

1.04
7.99
Earnings Yield (Greenblatt) 923.50
OCRX's Earnings Yield (Greenblatt) is ranked higher than
99% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. OCRX: 923.50 )
OCRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 11489.4
Current: 923.5

0
11489.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:6TY1.Germany
Ocera Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.
» More Articles for OCRX

Headlines

Articles On GuruFocus.com
Three Insider Buys at 52-Week Lows Jul 22 2014 
Weekly CEO Buys Highlight: OPK, QTET, MIC, FAST, OCRX Jul 21 2014 
Top 3 Insider Buys of the Week Jul 19 2013 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Aug 27 2014
OCERA THERAPEUTICS, INC. Financials Aug 22 2014
OCERA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 13 2014
Ocera Reports Second Quarter 2014 Financial Results Aug 11 2014
Ocera Announces Appointment of Rajiv Patni, M.D. as Chief Development Officer Aug 11 2014
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change... Aug 11 2014
Ocera Announces Appointment of Rajiv Patni, M.D. as Chief Development Officer Aug 11 2014
Ocera Reports Second Quarter 2014 Financial Results Aug 11 2014
Ocera Therapeutics to Announce Second Quarter Financial Results Jul 31 2014
Ocera Therapeutics to Announce Second Quarter Financial Results Jul 31 2014
Three Insider Buys at 52-Week Lows Jul 22 2014
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jul 10 2014
Why Ocera Therapeutics (OCRX) Stock Is Plunging Today Jul 10 2014
Ocera Therapeutics Raises $25.2 Million in Public Offering Jul 10 2014
Ocera Therapeutics 4.2M share Spot Secondary priced at $6.00 Jul 10 2014
Ocera Therapeutics Raises $25.2 Million in Public Offering Jul 10 2014
Ocera Therapeutics Announces Proposed Public Offering of Common Stock Jul 09 2014
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Jul 09 2014
Ocera Therapeutics Announces Proposed Public Offering of Common Stock Jul 09 2014
Ocera Therapeutics to Present at the JMP Securities Healthcare Conference 2014 Jun 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK